口服联合抗病毒治疗对丙型肝炎病毒基因4型感染的真实世界有效性与安全性
本研究为队列研究,纳入全国数据库中的HCV基因4型感染患者,分别接受OMV/PTVr+RBV(n=122)或LDV/SOF±RBV(n=130)治疗并前瞻性随访。总体SVR12分别为96.2%和95.4%,肝硬化患者中分别为91.2%和93.2%;两种方案安全性良好。
要点
- OMV/PTVr+RBV组总体SVR12为96.2%,LDV/SOF±RBV组为95.4%。
- 肝硬化患者中SVR12分别为91.2%和93.2%,纤维化程度与SVR12无显著差异。
- 基线白蛋白<3.5 g/dL(OMV/PTVr组)和胆红素>2 mg/dL(两队列)与未获SVR显著相关。
核心结论
- 基于DAA的方案在真实世界基因4型HCV感染(含肝硬化和非肝硬化)患者中返回高SVR12率,与有限临床试验数据相当。
- 两种方案的安全性良好,与其他HCV基因型报告的安全性相当。
研究设计与样本
- 队列研究,纳入全国数据库中的HCV基因4型感染患者并前瞻性随访。
- OMV/PTVr+RBV组n=122,LDV/SOF±RBV组n=130。
- 分析人口学、临床和病毒学数据及严重不良事件(SAEs)。
主要发现
- 总体SVR12:OMV/PTVr+RBV组96.2%,LDV/SOF±RBV组95.4%。
- 肝硬化患者SVR12:OMV/PTVr+RBV组91.2%,LDV/SOF±RBV组93.2%。
- 两个治疗组中SVR12按纤维化程度均无显著差异(P=.243和P=.244)。
- 多变量分析:基线白蛋白<3.5 g/dL(OMV/PTVr组)和胆红素>2 mg/dL(两队列)与未获SVR显著相关(P<.05)。
- SAEs及SAE相关停药率:OMV/PTVr亚队列分别为5.7%和2.5%,LDV/SOF亚队列分别为4.6%和0.8%。
关键数值与推荐
- 总体SVR12:OMV/PTVr+RBV组96.2%,LDV/SOF±RBV组95.4%。
- 肝硬化患者SVR12:OMV/PTVr+RBV组91.2%,LDV/SOF±RBV组93.2%。
- SAEs发生率:OMV/PTVr亚队列5.7%,LDV/SOF亚队列4.6%;SAE相关停药率分别为2.5%和0.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 治疗组间存在差异,数据不能直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with hepatitis C virus (HCV) genotype 4 infection are poorly represented in clinical trials of second-generation direct-acting antiviral agents (DAAs). More data are needed to help guide treatment decisions. We investigated the effectiveness and safety of DAAs in patients with genotype 4 infection in routine practice. In this cohort study, HCV genotype 4-infected patients treated with ombitasvir/paritaprevir/ritonavir (OMV/PTVr) + ribavirin (RBV) (n=122) or ledipasvir/sofosbuvir (LDV/SOF) ± RBV (n=130) included in a national database were identified and prospectively followed up. Demographic, clinical and virologic data and serious adverse events (SAEs) were analyzed. Differences between treatment groups mean that data cannot be compared directly. Overall sustained virologic response at Week 12 post treatment (SVR12) was 96.2% with OMV/PTVr+RBV and 95.4% with LDV/SOF±RBV. In cirrhotic patients, SVR12 was 91.2% with OMV/PTVr+RBV and 93.2% with LDV/SOF±RBV. There was no significant difference in SVR12 according to degree of fibrosis in either treatment group (P = .243 and P = .244, respectively). On multivariate analysis, baseline albumin <3.5 g/dL (OMV/PTVr) and bilirubin >2 mg/dL (both cohorts) were significantly associated with failure to achieve SVR (P < .05). Rates of SAEs and SAE-associated discontinuation were 5.7% and 2.5%, respectively, in the OMV/PTVr subcohort and 4.6% and 0.8%, respectively, in the LDV/SOF subcohort. DAA-based regimens returned high rates of SVR12, comparable to limited data from clinical trials, in cirrhotic and non-cirrhotic HCV genotype 4 patients managed in a realworld setting. Safety profiles of both regimens were good and comparable to those reported for other HCV genotypes.
引用
- Crespo J, Calleja JL, Fernández I, et al. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clin Gastroenterol Hepatol. 2017. PMID: 28238958. doi:10.1016/j.cgh.2017.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。